High-Intensity Exercise Promotes Deleterious Cardiovascular Remodeling in a High-Cardiovascular-Risk Model: A Role for Oxidative Stress.

animal model cardiovascular remodeling high cardiovascular risk kidney disease metabolic syndrome strenuous exercise

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
20 Jul 2023
Historique:
received: 23 04 2023
revised: 01 07 2023
accepted: 03 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Although the benefits of moderate exercise in patients at high cardiovascular risk are well established, the effects of strenuous exercise remain unknown. We aimed to study the impact of strenuous exercise in a very high cardiovascular risk model. Nephrectomized aged Zucker obese rats were trained at a moderate (MOD) or high (INT) intensity or were kept sedentary (SED) for 10 weeks. Subsequently, echocardiography and ex vivo vascular reactivity assays were performed, and blood, aortas, perivascular adipose tissue (PVAT), and left ventricles (LVs) were harvested. An improved risk profile consisting of decreased body weight and improved response to a glucose tolerance test was noted in the trained groups. Vascular reactivity experiments in the descending thoracic aorta demonstrated increased endothelial NO release in the MOD group but not in the INT group, compared with SED; the free radical scavenger TEMPOL improved endothelial function in INT rats to a similar level as MOD. An imbalance in the expression of oxidative stress-related genes toward a pro-oxidant environment was observed in the PVAT of INT rats. In the heart, INT training promoted eccentric hypertrophy and a mild reduction in ejection fraction. Obesity was associated with LV fibrosis and a transition toward β-myosin heavy chain and the N2Ba titin isoform. Exercise reverted the myosin imbalance, but only MOD reduced the predominance of the N2Ba titin isoform. In conclusion, moderate exercise yields the most intense cardiovascular benefits in a high-cardiovascular-risk animal model, while intense training partially reverts them.

Identifiants

pubmed: 37508000
pii: antiox12071462
doi: 10.3390/antiox12071462
pmc: PMC10376780
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI19/00443
Organisme : Instituto de Salud Carlos III
ID : PI22/00953
Organisme : CERCA Institution
ID : NA
Organisme : Centro de Investigación en Red en Enfermedades Cardiovasculares
ID : 16/11/00354
Organisme : Consejo Superior de Derportes
ID : EXP_75119
Organisme : European Regional Development Fund (FEDER)
ID : NA

Références

Circulation. 2006 Apr 25;113(16):1966-73
pubmed: 16618817
Nat Rev Cardiol. 2017 Feb;14(2):88-101
pubmed: 27830772
J Am Coll Cardiol. 2004 Dec 21;44(12):2390-7
pubmed: 15607403
Am J Physiol Heart Circ Physiol. 2017 Sep 1;313(3):H459-H468
pubmed: 28550178
Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):423-36
pubmed: 16506274
Med Sci Sports Exerc. 2011 Jul;43(7):1334-59
pubmed: 21694556
Redox Biol. 2019 Sep;26:101285
pubmed: 31374361
J Nat Sci. 2017 Apr;3(4):
pubmed: 28670620
PLoS One. 2013 Aug 29;8(8):e72959
pubmed: 24009719
Curr Obes Rep. 2016 Dec;5(4):424-434
pubmed: 27744513
J Appl Physiol (1985). 2002 Aug;93(2):788-96
pubmed: 12133893
Transl Res. 2014 Oct;164(4):323-35
pubmed: 24880146
Age (Dordr). 2015 Aug;37(4):9806
pubmed: 26228838
Curr Obes Rep. 2020 Dec;9(4):571-581
pubmed: 32870465
Lancet. 2010 Jun 12;375(9731):2073-81
pubmed: 20483451
Circulation. 2017 Jul 11;136(2):138-148
pubmed: 28450347
Med Sci Sports Exerc. 2010 Feb;42(2):346-54
pubmed: 19927025
Med Sci Sports Exerc. 2007 Jan;39(1):75-82
pubmed: 17218887
Antioxidants (Basel). 2023 Feb 16;12(2):
pubmed: 36830059
Eur J Pharmacol. 2016 Feb 15;773:13-23
pubmed: 26801071
Front Physiol. 2020 Jan 09;10:1550
pubmed: 31992987
Circ Res. 2021 Apr 2;128(7):951-968
pubmed: 33793327
J Clin Invest. 1989 Dec;84(6):1693-700
pubmed: 2687327
Circulation. 2015 Feb 24;131(8):721-9
pubmed: 25688148
Med Sci Sports Exerc. 2011 Jun;43(6):974-81
pubmed: 21085033
Hypertens Res. 2016 Feb;39(2):70-8
pubmed: 26537830
Front Physiol. 2019 Jul 12;10:889
pubmed: 31354526
PLoS One. 2015 Jun 12;10(6):e0130031
pubmed: 26070197
Pharmacology. 1996 Jan;52(1):16-24
pubmed: 8966198
J Mol Cell Cardiol. 2009 Apr;46(4):490-8
pubmed: 19639676
JACC Basic Transl Sci. 2022 Jul 13;7(7):681-693
pubmed: 35958697
Nat Commun. 2015 Jan 19;6:6018
pubmed: 25598495
JAMA Cardiol. 2019 Feb 1;4(2):174-181
pubmed: 30698608
Mayo Clin Proc. 2014 Sep;89(9):1187-94
pubmed: 25128072
Eur Heart J. 2021 Sep 14;42(35):3526-3528
pubmed: 34297811
Eur Heart J. 2023 Jul 7;44(26):2388-2399
pubmed: 36881712
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Heart. 2014 Jul;100(13):1043-9
pubmed: 24829374
Circ Res. 2016 Feb 19;118(4):620-36
pubmed: 26892962
Circulation. 2017 Jul 11;136(2):126-137
pubmed: 28465287
Eur Heart J. 2008 Aug;29(15):1903-10
pubmed: 18426850
Int J Obes. 1986;10(3):175-83
pubmed: 3759327
Circulation. 2011 Jan 4;123(1):13-22
pubmed: 21173356

Auteurs

Aline Meza-Ramos (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Medicine Department, Universitat de Barcelona, 08036 Barcelona, Spain.
Consejo Nacional de Ciencia y Tecnología (CONACyT), Ciudad de México 03940, Mexico.

Anna Alcarraz (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Medicine Department, Universitat de Barcelona, 08036 Barcelona, Spain.

Marta Lazo-Rodriguez (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), 08036 Barcelona, Spain.

Gemma Sangüesa (G)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.

Elisenda Banon-Maneus (E)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), 08036 Barcelona, Spain.

Jordi Rovira (J)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), 08036 Barcelona, Spain.

Maria Jose Ramirez-Bajo (MJ)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), 08036 Barcelona, Spain.

Marta Sitges (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Medicine Department, Universitat de Barcelona, 08036 Barcelona, Spain.
Cardiovascular Institute, Clínic Barcelona, 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Lluís Mont (L)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Medicine Department, Universitat de Barcelona, 08036 Barcelona, Spain.
Cardiovascular Institute, Clínic Barcelona, 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Pedro Ventura-Aguiar (P)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), 08036 Barcelona, Spain.
Department of Nephrology and Kidney Transplantation, Clínic Barcelona, 08036 Barcelona, Spain.

Montserrat Batlle (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Eduard Guasch (E)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Medicine Department, Universitat de Barcelona, 08036 Barcelona, Spain.
Cardiovascular Institute, Clínic Barcelona, 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Classifications MeSH